Intel stock extends gains after report of possible U.S. government stake
Investing.com - Deutsche Bank (ETR:DBKGn) has lowered its price target on Schott Pharma AG (ETR:1SXP) to €29.00 from €31.00 while maintaining a Buy rating following the company’s third-quarter results.
The Q3 release aligned with Schott Pharma’s pre-release from last week, showing modest sales growth but significant margin expansion, according to Deutsche Bank.
The bank adjusted its model after Schott Pharma revised its guidance, reducing organic sales growth expectations to approximately 6% from previous high-single digits, while raising its adjusted EBITDA margin forecast to approximately 28% from 26.9%.
Deutsche Bank reduced its adjusted EPS estimate by 5% for fiscal year 2026 and by a slightly higher rate for subsequent years, citing a higher tax rate and foreign exchange effects as contributing factors.
Despite the price target reduction, Deutsche Bank maintained its Buy rating, noting that Schott Pharma should continue to capitalize on growth and margin expansion opportunities, with the current valuation at 22x 2026 estimated P/E described as undemanding.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.